Glycomet 500 SR (Metformin)

Product Overview

Glycomet 500 SR is a prescription oral antidiabetic medication manufactured by USV Pvt Ltd. Each sustained‑release tablet delivers 500 mg of Metformin and comes in strips of 20 tablets. Pack sizes of 100, 200, or 300 tablets are available to support long‑term treatment. The film‑coated tablets are stored at room temperature and are shipped within 6–15 days, ensuring a reliable supply for pharmacies and patients. The product undergoes strict quality control to meet regulatory standards, providing a consistent dose of the active ingredient for effective blood‑glucose management and ensures therapeutic reliability throughout the treatment course.

What is Glycomet 500 SR (Metformin)

Metformin, the active component of Glycomet 500 SR, belongs to the biguanide class of antihyperglycemic agents. It lowers blood glucose primarily by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues. The drug is referenced in major databases such as the NIH and FDA, confirming its established safety and efficacy. When used alone, Metformin has a low risk of hypoglycemia and has been associated with cardiovascular benefits in patients with type 2 diabetes. Its sustained‑release formulation maintains steady plasma levels, enhancing tolerability compared with immediate‑release versions and supports long‑term glycemic stability when combined with lifestyle modifications significantly.

Uses and Benefits

The primary indication for Glycomet 500 SR is the improvement of glycemic control in adults with type 2 diabetes. Clinical trials demonstrate that the 500 mg sustained‑release tablet reduces fasting and post‑prandial glucose, leading to an average HbA1c decrease of 1–2 %. Unlike many older agents, Metformin is weight‑neutral and does not cause fluid retention. In addition, long‑term studies suggest a possible reduction in cardiovascular events, reinforcing its role as a first‑line therapy. The sustained‑release design delivers the drug steadily over 24 hours, which helps maintain consistent glucose lowering while minimizing gastrointestinal discomfort compared with immediate‑release formulations and improves overall patient adherence to therapy significantly.

How It Works

Metformin lowers blood glucose through several interconnected mechanisms. It inhibits hepatic gluconeogenesis, decreasing the liver’s output of glucose. The drug also enhances insulin action in muscle and fat tissue, promoting greater glucose uptake. Research indicates that Metformin modulates gut microbiota, increasing the production of short‑chain fatty acids that may further improve insulin sensitivity. These actions occur without stimulating insulin release from the pancreas, which gives Metformin a low risk of hypoglycemia when used alone. The combined effect results in a modest but clinically meaningful reduction in circulating glucose and supports sustained improvements in metabolic health when combined with diet and exercise over time significantly.

Dosage Guidelines

Therapy with Glycomet 500 SR typically begins with one 500 mg tablet taken once daily with the evening meal to reduce gastrointestinal side effects. After at least one week, the dose may be increased by 500 mg at weekly intervals based on blood‑glucose response, aiming for a total daily dose of 1000–2000 mg, often divided into two doses. The tablet must be swallowed whole; crushing or chewing can damage the sustained‑release coating. Renal function should be checked regularly, and if the estimated glomerular filtration rate falls below 45 mL/min/1.73 m², the dose should be reduced or the medication discontinued. Detailed prescribing information is available on the MedlinePlus website for patients.

Side Effects

Adverse reactions to Glycomet 500 SR are usually mild and confined to the gastrointestinal tract, manifesting as nausea, diarrhea, abdominal discomfort, or a transient metallic taste. These symptoms often improve with continued therapy or when the dose is titrated more slowly. Although rare, a serious condition known as lactic acidosis can occur, especially in individuals with impaired kidney function, severe liver disease, or those who develop hypoxia during surgery. Signs include unexplained fatigue, muscle pain, abdominal pain, rapid breathing, and dizziness; immediate medical attention is required if they appear. Hypoglycemia is uncommon with Metformin alone but may arise when combined with insulin or sulfonylureas, necessitating regular glucose monitoring.

Warnings and Precautions

Glycomet 500 SR is contraindicated in patients with an eGFR below 30 mL/min/1.73 m², in those experiencing acute metabolic acidosis, and in individuals with known hypersensitivity to Metformin or any tablet excipients. Additional caution is advised for patients with hepatic impairment, heart failure, or conditions that predispose to hypoxia. Before starting therapy, baseline renal function should be assessed, and eGFR re‑checked every three to six months. The drug must be withheld for at least 24 hours before and after radiographic imaging that uses iodinated contrast to prevent kidney injury. Pregnant or lactating women should consult a physician, as the medication crosses the placenta and is excreted in breast milk in low amounts.

Frequently Asked Questions

Q: What is the recommended starting dose of Glycomet 500 SR? A: The recommended starting dose of Glycomet 500 SR is one 500 mg tablet taken once daily with the evening meal. This timing helps to minimize gastrointestinal side effects. After a minimum of one week, the dose may be increased by 500 mg at weekly intervals, guided by fasting glucose or HbA1c results, until the desired glycemic target is approached. The tablet must be swallowed whole with water; it should not be split, crushed, or chewed, as doing so can compromise the sustained‑release coating and increase the risk of adverse effects.

Q: Can Glycomet 500 SR be used in patients with kidney disease? A: Glycomet 500 SR should not be used in patients whose estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m², as this indicates severe renal impairment and raises the risk of drug accumulation and lactic acidosis. For patients with moderate renal dysfunction (eGFR between 30 and 45 mL/min/1.73 m²), the dose must be reduced and therapy monitored closely, often with more frequent assessment of kidney function. Any changes to the dosing regimen should be made only under the supervision of a qualified healthcare professional who can evaluate the patient’s overall health status and laboratory results.

Q: How long does it take to see a reduction in HbA1c levels? A: Patients typically observe a reduction in their HbA1c levels after approximately four to six weeks of consistent Glycomet 500 SR therapy, provided the medication is taken as prescribed and combined with lifestyle modifications such as diet and exercise. The magnitude of the decrease varies among individuals; clinical trials have reported average reductions of about 1 to 2 percent in HbA1c after several months of treatment. However, some patients may experience a more rapid response, while others may require a longer duration before achieving the desired target, underscoring the importance of regular glucose monitoring and follow‑up with a healthcare provider.

Q: Are there dietary restrictions while taking Glycomet 500 SR? A: There are no strict dietary restrictions imposed by Glycomet 500 SR, but achieving optimal glycemic control is enhanced when patients adopt a balanced, nutrient‑dense diet that emphasizes whole grains, lean proteins, and ample vegetables while limiting excessive simple sugars and refined carbohydrates. Regular physical activity, such as moderate‑intensity aerobic exercise for at least 150 minutes per week, further improves insulin sensitivity and helps maintain stable blood‑glucose levels. Patients should work with a dietitian or diabetes educator to create a personalized nutrition plan that aligns with their overall health goals and medication regimen.

Q: Is Glycomet 500 SR safe during pregnancy or breastfeeding? A: Metformin is classified as a Category B medication in pregnancy, indicating that animal studies have not demonstrated a risk to the fetus and that there is no well‑controlled studies in pregnant women; however, its use for type 2 diabetes during pregnancy should only occur after a thorough discussion with a qualified obstetrician or endocrinologist who can weigh the potential benefits against any unknown risks. In lactating women, Metformin is excreted into breast milk at low concentrations, and current evidence suggests that infant exposure is minimal; nevertheless, nursing mothers should consult their physician to determine whether continued use is appropriate and to monitor the infant’s health if the medication is continued.